Diabetes mellitus affects almost half a billion patients worldwide and results from either
destruction of β‐cells responsible for insulin secretion or increased tissue resistance to …

Diabetic kidney disease (DKD) is one of the most common causes of end-stage renal
disease worldwide. The treatment of DKD is strongly associated with clinical outcomes in …

Chronic kidney disease (CKD) is associated with increased morbidity and mortality,
especially from cardiovascular (CV) causes, and especially in people with diabetes mellitus …

Diabetic kidney disease (DKD), previously encountered predominantly in adult patients, is
rapidly gaining center stage as a childhood morbidity and one that pediatric nephrologists …

Nowadays, type II diabetes mellitus, more specifically ensuing diabetic nephropathy, and
severe COVID-19 disease are known to be closely associated. The exact mechanisms …

A design of experiments (DoE) approach was applied to the development and optimization
of the manufacturing process to prepare linagliptin. DoE techniques such as a central …

Dipeptidyl peptidase-4 (DPP-4) is expressed ubiquitously in many tissues, including kidney,
respiratory tract, and immune cells. Human DPP-4 has been identified as a functional …

Diabetes mellitus is the leading cause of end-stage renal disease, and uncontrolled
hyperglycemia is directly related to the increased mortality in this setting. As kidney function …

Dapagliflozin, a selective sodium–glucose co-transporter-2 inhibitor, and linagliptin, a
competitive, reversible dipeptidyl peptidase-4 inhibitor, are commonly prescribed …

Die chronische Nierenkrankheit (CKD:„chronic kidney disease “) stellt eine der häufigsten
Folgekomplikationen bei Menschen mit Diabetes mellitus dar und erhöht exzessiv die …